Modern approaches to pharmacotherapy of postpartum depression
|
Full Text:
Subscribers Only
|
Suggested citation:
Useinova AN, Fedorec AV, Kut'kina VM, et al. [Modern approaches to pharmacotherapy of postpartum depression]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2025;(3):95-102. Russian
This scientific review presents data on modern standards of pharmacotherapy, hormonal treatment and new analogs of allopregnanolone, and discusses modern concepts of the pathophysiology of postpartum depression. The results of various clinical trials are presented, which were selected from such electronic information resources as the Elsevier library, PubMed, NCBI, Google Scholar, eLIBRARY. All of them confirmed the effectiveness of allopregnanolone analogues in alleviating the symptoms of postpartum depression, which leads to an improvement in the quality of life of mothers. The development of new antidepressants – allopregnanolone analogues, registration and implementation of existing ones, is a promising direction in Russia.
Keywords postpartum depression; allopregnanolone; neuroactive steroids; brexanolone; zuranolone
1. Liu X, Wang S, Wang G. Prevalence and Risk Factors of Postpartum Depression in Women: A Systematic Review and Meta-analysis. J Clin Nurs. 2022;31(19-20):2665–77. PMID: 34750904; DOI: 10.1111/jocn.16121 2. Makarova MA, Tikhonova YuG, Avdeeva TI, et al. [Postpartum depression – risk factors, clinical and treatment aspects]. Nevrologiya, neyropsikhiatriya, psikhosomatika [Neurology, neuropsychiatry, psychosomatics]. 2021;(4):75–80. (In Russ.) 3. Suri R, Stowe ZN, Cohen LS, et al. Prospective Longitudinal Study of Predictors of Postpartum-Onset Depression in Women With a History of Major Depressive Disorder. J Clin Psychiatry. 2017;78(8):1110–6. PMID: 28297589; DOI: 10.4088/JCP.15m10427 4. Slomian J, Honvo G, Emonts P, et al. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. Womens Health. 2019;15:1745506519844044. PMID: 31035856; DOI: 10.1177/1745506519844044 5. Drury SS, Scaramella L, Zeanah CH. The Neurobiological Impact of Postpartum Maternal Depression: Prevention and Intervention Approaches. Child Adolesc Psychiatr Clin N Am. 2016;25(2):179–200. PMID: 26980123; DOI: 10.1016/j.chc.2015.11.001 6. Kieviet N, de Jong F, Scheele F, et al. Use of antidepressants during pregnancy in the Netherlands: observational study into postpartum interventions. BMC Pregnancy Childbirth. 2017;17(1):23. PMID: 28077067; DOI: 10.1186/s12884-016-1184-5 7. Anderson PO. Antidepressants and Breastfeeding. Breastfeed Med. 2021;16(1):5–7. PMID: 33237799; DOI: 10.1089/bfm.2020.0350 8. Chibanda D, Shetty AK, Tshimanga M. Group problem-solving therapy for postnatal depression among HIV-positive and HIV-negative mothers in Zimbabwe. J Int Assoc Provid AIDS Care. 2014;13(4):335–41. PMID: 23881909; DOI: 10.1177/2325957413495564 9. Cuomo A, Maina G, Neal SM, et al. Using sertraline in postpartum and breastfeeding: balancing risks and benefits. Expert Opin Drug Saf. 2018;17(7):719–25. PMID: 29927667; DOI: 10.1080/14740338.2018.1491546 10. Uguz F, Sharma V. Mood stabilizers during breastfeeding: a systematic review of the recent literature. Bipolar Disord. 2016;18(4):325–33. PMID: 27297617; DOI: 10.1111/bdi.12398 11. Misri S, Swift E, Abizadeh J, et al. Overcoming functional impairment in postpartum depressed or anxious women: a pilot trial of desvenlafaxine with flexible dosing. Ther Adv Psychopharmacol. 2016;6(4):269–76. PMID: 27536346; DOI: 10.1177/2045125316656297 12. Gregoire AJ, Kumar R, Everitt B, et al. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996;347(9006):930–3. PMID: 8598756; DOI: 10.1016/s0140-6736(96)91414-2 13. Li HJ, Martinez PE, Li X, et al. Transdermal estradiol for postpartum depression: results from a pilot randomized, double-blind, placebo-controlled study. Arch Womens Ment Health. 2020;23(3):401–12. PMID: 31372757; DOI: 10.1007/s00737-019-00991-3 14. Kettunen P, Koistinen E, Hintikka J, et al. Oestrogen therapy for postpartum depression: efficacy and adverse effects. A double-blind, randomized, placebo-controlled pilot study. Nord J Psychiatry. 2022;76(5):348–57. PMID: 34533410; DOI: 10.1080/08039488.2021.1974556 15. Dennis CL, Ross LE, Herxheimer A. Oestrogens and progestins for preventing and treating postpartum depression. Cochrane Database Syst Rev. 2008;2008(4):CD001690. PMID: 18843619; DOI: 10.1002/14651858.CD001690.pub2 16. Singata-Madliki M, Hofmeyr GJ, Lawrie TA. The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised controlled trial. J Fam Plann Reprod Health Care. 2016;42(3):171–6. PMID: 27030698; DOI: 10.1136/jfprhc-2015-101334 17. Pieh Holder KL. Contraception and Breastfeeding. Clin Obstet Gynecol. 2015;58(4):928–35. PMID: 26457854; DOI: 10.1097/GRF.0000000000000157 18. Stefaniak M, Dmoch-Gajzlerska E, Jankowska K, et al. Progesterone and Its Metabolites Play a Beneficial Role in Affect Regulation in the Female Brain. Pharmaceuticals (Basel). 2023;16(4):520. PMID: 37111278; DOI: 10.3390/ph16040520 19. Schock H, Zeleniuch-Jacquotte A, Lundin E, et al. Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. BMC Pregnancy Childbirth. 2016;16(1):146. PMID: 27377060; DOI: 10.1186/s12884-016-0937-5 20. McEvoy K, Payne JL, Osborne LM. Neuroactive Steroids and Perinatal Depression: a Review of Recent Literature. Curr Psychiatry Rep. 2018;20(9):78. PMID: 30094520; DOI: 10.1007/s11920-018-0937-4 21. Weingarten SJ, Osborne LM. Review of the Assessment and Management of Perinatal Mood and Anxiety Disorders. Focus (Am Psychiatr Publ). 2024;22(1):16–24. PMID: 38694149; DOI: 10.1176/appi.focus.20230023 22. Maguire J, McCormack C, Mitchell A, et al. Neurobiology of maternal mental illness. Handb Clin Neurol. 2020;171:97–116. PMID: 32736761; DOI: 10.1016/B978-0-444-64239-4.00005-9 23. Powell JG, Garland S, Preston K, Piszczatoski C. Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression. Ann Pharmacother. 2020;54(2):157–63. PMID: 31476884; DOI: 10.1177/1060028019873320 24. Martinez Botella G, Salituro FG, Harrison BL, et al. Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid) A Receptor. J Med Chem. 2017;60(18):7810–9. PMID: 28753313; DOI: 10.1021/acs.jmedchem.7b00846 25. Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2023;80(2):191. PMID: 34190962; DOI: 10.1001/jamapsychiatry.2022.4181 26. Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. Zuranolone for the Treatment of Postpartum Depression. Am J Psychiatry. 2023;180(9):668–75. PMID: 37491938; DOI: 10.1176/appi.ajp.20220785 27. Deligiannidis KM, Bullock A, Nandy I, et al. Zuranolone Concentrations in the Breast Milk of Healthy, Lactating Individuals: Results From a Phase 1 Open-Label Study. J Clin Psychopharmacol. 2024;44(4):337–44. PMID: 38739007; DOI: 10.1097/JCP.0000000000001873 28. Hecking J, Davoudian PA, Wilkinson ST. Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders. Chronic Stress (Thousand Oaks). 2021;5:24705470211020446. PMID: 34124495; DOI: 10.1177/24705470211020446 29. De SK. Ganaxolone: First FDA-approved Medicine for the Treatment of Seizures Associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder. Curr Med Chem. 2024;31(4):388–92. PMID: 36959132; DOI: 10.2174/0929867330666230320123952 30. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia. 2017;58(2):181–221. PMID: 28111749; DOI: 10.1111/epi.13634 31. Marinus Pharmaceuticals 2023a. A clinical trial of intravenous (IV) ganaxolone in women with postpartum depression. National Library of Medicine (S). 2023. URL: https://clinicaltrials.gov/study/NCT03228394 (accessed on: 13.12.2024). 32. Marinus Pharmaceuticals 2023b. A clinical trial of oral ganaxolone in women with postpartum depression. National Library of Medicine (US). 2023. URL: https://clinicaltrials.gov/study/NCT03460756 (accessed on: 13.12.2024). 33. Cerne R, Lippa A, Poe MM, et al. GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors. Pharmacol Ther. 2022;234:108035. PMID: 34793859; DOI: 10.1016/j.pharmthera.2021.108035 34. Gerbera Therapeutics Inc 2023. Nora 520. URL: https://www.gerberarx.com/en/product/detail/NORA520 (accessed on: 13.12.2024). 35. LYT-300. A range of neurological and neuropsychological conditions, including anxiety, mood disorders and Fragile X-associated Tremor/Ataxia Syndrome. PuretechHealth. URL: https://puretechhealth.com/programs/details/lyt-300 (accessed on: 13.12.2024). 36. Brii Biosciences Limited 2023b. Brii Biosciences announces top-line results from phase 1 study of BRII-296, A long-acting therapy in development for postpartum depression. PRNewswire. URL: https://www.prnewswire.com/news-releases/brii-biosciences-announces-top-line-results-from-phase-1-study-of-brii-296-a-long-acting-therapy-in-development-for-postpartum-depression-301632804.html (accessed on: 13.12.2024). 37. Carlson K, Mughal S, Azhar Y, et al. Postpartum Depression. StatPearls. 2024;12:1–7. PMID: 30085612 38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5TR). 2022. American Psychiatric Association Publishing. 39. Chen G, Xu M, Chen Z, Yang F. Clinical applications of small-molecule GABAAR modulators for neurological disorders. Bioorg Chem. 2024;153:107983. PMID: 39581171; DOI: 10.1016/j.bioorg.2024.107983
Article Metrics
Metrics powered by PLOS ALM